The document summarizes three reports by DelveInsight on Vimpat API, Wet AMD Epidemiology, and Xarelto API. The Vimpat report provides details on the drug's manufacturer, mechanism of action, clinical trials, sales forecasts and patents. The Wet AMD report describes the disease, prevalence in the US expected to grow to 3 million cases by 2020, and risk factors like increasing with age. The Xarelto report similarly provides manufacturer details, mechanism, clinical trials, sales forecasts and competitive landscape. All reports use primary and secondary research from various sources.

1. 1/2
By consulting services August 24, 2021
List of 3 Reports by DelveInsight
telegra.ph/List-of-3-Reports-by-DelveInsight-08-24
Vimpat API Insight, 2021 report by DelveInsight provides product and API
manufacturer’s details across US, Europe, China and India for Vimpat. It includes Vimpat
overview, mechanism, regulatory milestones, deals & partnerships, clinical trials and
other development activities. It further provides Vimpat's patents information (US & EU).
It also features the historical and forecasted sales of Vimpat till 2023. The report also
highlights vimpat patent expiration market competition and emerging therapies
which are in the same space as Vimpat.
Data used in the report are sourced primarily from internal databases, primary and
secondary research and in-house analysis by DelveInsight's team of industry experts.
Information and data from the secondary sources have been obtained from various
printable and non-printable sources like search engines, news websites, global regulatory
authorities websites, trade journals, white papers, magazines, books, trade associations,
industry associations, industry portals and access to available databases.
Age-related macular degeneration (AMD) is a leading cause of severe, irreversible
blindness in developed countries worldwide, profoundly affecting the quality of life of
affected individuals. The increase in life expectancy bringing growth in the number of
reported cases adds a significant burden on the health care systems with the expensive
current standard of care.
Wet AMD Epidemiology is a type of AMD which is characterized by abrupt central
vision loss caused by abnormal blood vessels that bleed or leak fluid, which may swell and
damage the macula. Wet-AMD also referred to as neovascular AMD, accounts for roughly

2. 2/2
10% of AMD cases, but almost 90% of AMD-related central vision loss. Although 80% of
the patients have non-neovascular or atrophic AMD, the disease's neovascular form is
responsible for nearly 90% of the severe, central visual acuity loss associated with AMD.
AMD’s progression leads to loss of central vision, which adversely affects the quality of
life. Although AMD’s exact functional pathogenesis is not fully understood, there have
been recent improvements in genetic technologies leading to the identification of various
polymorphisms that have shown to harbor unique AMD associations.
In the case of the United States, as per estimates, approximately 11 to 15 million people in
the United States have AMD, and more than 1.7 million Americans have the advanced
form of the disease. About 200,000 new cases of wet AMD are diagnosed each year in
North America. Due to the aging population, the National Eye Institute estimates that the
prevalence of advanced AMD will grow to nearly 3 million by 2020. Wet macular
degeneration accounts for approximately 10 percent of cases, but results in 90 percent of
legal blindness. This assumption was particularly used to obtain the burden of Wet-AMD
among the prevalent AMD population. Age is a prominent risk factor for Age-related
macular degeneration. The risk of getting advanced age-related macular degeneration
increase from 2% for those ages 50–59 to nearly 30% for those over the age of 75.
"Xarelto - API Insight, 2021" report by DelveInsight provides product and API
manufacturers details across US, Europe, China and India for Xarelto. It includes Xarelto
overview, mechanism, regulatory milestones, deals & partnerships, clinical trials and
other development activities. It further provides Xarelto's patents information (US & EU).
It also features the historical and forecasted sales of Xarelto till 2023. The report also
highlights Xarelto competitors' market competition and emerging therapies which are
in the same space as Xarelto.
Data used in the report are sourced primarily from internal databases, primary and
secondary research and in-house analysis by DelveInsight's team of industry experts.
Information and data from the secondary sources have been obtained from various
printable and non-printable sources like search engines, news websites, global regulatory
authorities websites, trade journals, white papers, magazines, books, trade associations,
industry associations, industry portals and access to available databases.
Read Recommended Articles-
· Market Research Firms in Gurgaon
· Skillbase Consulting